Filter News

BioScrip Provides Update on Annual Form 10-K Filing Status

Published: Mar 15, 2018

DENVER--(BUSINESS WIRE)-- BioScrip Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that it will be filing a Form 12b-25 with the U.S. Securities and Exchange Commission to automatically extend the date for filing its Annual Report on Form 10-K for the year ended December 31, 2017 by 15 days in order to finalize the accounting review announced in its earnings release dated March 8, 2018. As previously disclosed, the Company, as part of its accounting review prior to filing the Form 10-K, identified a series of transactions incorrectly accounted for predominately related to certain balance sheet suspense and clearing accounts. These errors appear clerical in nature. The Company plans to disclose a material weakness related to this matter. The accounting review is nearing completion and the Company expects to be able to file timely its upcoming Form 10-K.

About BioScrip, Inc.
BioScrip, Inc. is the largest independent national provider of infusion and home care management solutions, with approximately 2,200 teammates and nearly 80 service locations across the U.S. BioScrip partners with physicians, hospital systems, payors, pharmaceutical manufacturers and skilled nursing facilities to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.

Back to news